COVAXIN demonstrated 81% interim efficacy in preventing COVID-19 in those without prior infection after the second dose
Bharat Biotech announced the first interim analysis of its BBV152 (COVAXIN). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical...